Trial
NCT05724602
Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase IISUSPENDEDOTHER/UNKNOWNConfidence: LOW
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators
Merck KGaA, Darmstadt, Germany
Condition
Locally Advanced Head and Neck Squamous Cell Carcinoma
Intervention
Xevinapant
Why stopped
discontinuation of all ongoing studies involving xevinapant
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-08-27